Vaccines and Dementia: Part II. Efficacy of BCG and Other Vaccines Against Dementia
Journal of Alzheimer’s Disease · 19.03.2024 · 98 (2) · 361-372
DOI: 10.3233/jad-231323 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 19.02.2024. Verfasst von Charles L Greenblatt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada (IMRIC), Hebrew University of Jerusalem, Jerusalem, I…. Hauptthemen laut MEDLINE: Tuberculosis Vaccines, Alzheimer Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
There is growing awareness that infections may contribute to the development of senile dementia including Alzheimer’s disease (AD), and that immunopotentiation is therefore a legitimate target in the management of diseases of the elderly including AD. In Part I of this work, we provided a historical and molecular background to how vaccines, adjuvants, and their component molecules can elicit broad-spectrum protective effects against diverse agents, culminating in the development of the tuberculosis vaccine strain Bacille Calmette–Guérin (BCG) as a treatment for some types of cancer as well as a prophylactic against infections of the elderly such as pneumonia. In Part II, we critically review studies that BCG and other vaccines may offer a measure of protection against dementia development. Five studies to date have determined that intravesicular BCG administration, the standard of care for bladder cancer, is followed by a mean ∼45% reduction in subsequent AD development in these patients. Although this could potentially be ascribed to confounding factors, the finding that other routine vaccines such as against shingles (herpes zoster virus) and influenza (influenza A virus), among others, also offer a degree of protection against AD (mean 29% over multiple studies) underlines the plausibility that the protective effects are real. We highlight clinical trials that are planned or underway and discuss whether BCG could be replaced by key components of the mycobacterial cell wall such as muramyl dipeptide. We conclude that BCG and similar agents merit far wider consideration as prophylactic agents against dementia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada (IMRIC), Hebrew University of Jerusalem, Jerusalem, Israel.
- Division of Infection Medicine, University of Edinburgh Medical School, Edinburgh, UK.
Zitieren
APA
Greenblatt, C. L., & Lathe, R. (2024). Vaccines and Dementia: Part II. Efficacy of BCG and Other Vaccines Against Dementia. Journal of Alzheimer’s Disease, 98(2), 361-372. https://doi.org/10.3233/jad-231323
Vancouver
Greenblatt CL, Lathe R. Vaccines and Dementia: Part II. Efficacy of BCG and Other Vaccines Against Dementia. Journal of Alzheimer’s Disease. 2024;98(2):361-372. doi:10.3233/jad-231323
BibTeX
@article{Greenblatt2024,
author = {Greenblatt, Charles L and Lathe, Richard},
title = {Vaccines and Dementia: Part II. Efficacy of BCG and Other Vaccines Against Dementia},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
volume = {98},
number = {2},
pages = {361--372},
doi = {10.3233/jad-231323}
}
EUVIMED